Company news
Aprea Therapeutics, Inc. news in 2020
Aprea Therapeutics, Inc.'s news releases, calls and decks from 2020, newest first.
Aprea Therapeutics Announces Results of Primary Endpoint from Phase 3 Trial of Eprenetapopt in TP53 Mutant Myelodysplastic Syndromes (MDS)
December 27, 2020
Aprea Therapeutics Receives FDA Fast Track Designation for Eprenetapopt in the Treatment of TP53 Mutant Acute Myeloid Leukemia (AML)
November 29, 2020
Aprea Therapeutics Reports Third Quarter 2020 Financial Results and Provides Update on Business Operations
November 4, 2020
Aprea Therapeutics Launches Disease Awareness Website for Healthcare Professionals, p53reactivation.com
October 13, 2020
Aprea Therapeutics Receives OK from FDA to Initiate Phase 1 Clinical Studies for Next-Generation Mutant p53 Reactivator, APR-548
October 6, 2020
Aprea Therapeutics Appoints Michael A. Kelly to Board of Directors
September 28, 2020
Aprea Therapeutics Promotes Gregory S. Wessels to Chief Commercial Officer and Announces Governance Changes
September 17, 2020
Aprea Therapeutics Reports Second Quarter 2020 Financial Results and Provides Update on Business Operations
August 10, 2020
Aprea Therapeutics Announces Expansion of Clinical Trial Evaluating Eprenetapopt for the Front-Line Treatment of TP53 Mutant Acute Myeloid Leukemia (AML)
July 15, 2020
Aprea Therapeutics Appoints Fouad Namouni, M.D. and Richard Peters, M.D., Ph.D. to Board of Directors
June 28, 2020
Aprea Therapeutics Completes Full Enrollment of Phase 3 Clinical Trial in TP53 Mutant Myelodysplastic Syndromes (MDS)
June 2, 2020
Aprea Therapeutics Reports First Quarter 2020 Financial Results and Provides Update on Business Operations
May 14, 2020
Aprea Therapeutics Launches New Corporate Website - www.aprea.com
April 5, 2020
Aprea Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
March 25, 2020
Aprea Therapeutics Appoints Gregory S. Wessels as Vice President, Commercial
February 12, 2020
Aprea Therapeutics Receives FDA Breakthrough Therapy Designation for APR-246 in Combination with Azacitidine for the Treatment of Myelodysplastic Syndromes (MDS) with a TP53 Mutation
January 29, 2020
Decks in 2020
- J.P. Morgan 38th Annual Healthcare Conference 2020
Conference · 20 slides · Jan 13, 2020